Proteasome inhibitors prevent bi-directional HER2/estrogen-receptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2+/ER+ breast cancer cellsSonja Thaler(Heidelberg University)OncotargetAugust 14, 201710.18632/oncotarget.20261Cited by 1SaveCiteExport RISWatch citationsRelated PapersFunctional Characterization of Circulating Tumor Cells (CTCs) from Metastatic ER+/HER2− Breast Cancer Reveals Dependence on HER2 and FOXM1 for Endocrine Therapy Resistance and Tumor Cell Survival: Implications for Treatment of ER+/HER2− Breast Cancer|Cancers|2021|19